TY - JOUR
T1 - Recommendations for gonadotoxicity surveillance in male childhood, adolescent, and young adult cancer survivors
T2 - a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium
AU - Skinner, Roderick
AU - Mulder, Renee L.
AU - Kremer, Leontien C.
AU - Hudson, Melissa M.
AU - Constine, Louis S.
AU - Bardi, Edit
AU - Boekhout, Annelies
AU - Borgmann-Staudt, Anja
AU - Brown, Morven C.
AU - Cohn, Richard
AU - Dirksen, Uta
AU - Giwercman, Alexsander
AU - Ishiguro, Hiroyuki
AU - Jahnukainen, Kirsi
AU - Kenney, Lisa B.
AU - Loonen, Jacqueline J.
AU - Meacham, Lilian
AU - Neggers, Sebastian
AU - Nussey, Stephen
AU - Petersen, Cecilia
AU - Shnorhavorian, Margarett
AU - van den Heuvel-Eibrink, Marry M.
AU - van Santen, Hanneke M.
AU - Wallace, William H.B.
AU - Green, Daniel M.
N1 - Publisher Copyright:
© 2017 Elsevier Ltd
PY - 2017/2/1
Y1 - 2017/2/1
N2 - Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive organs can cause impaired spermatogenesis, testosterone deficiency, and physical sexual dysfunction in male pubertal, adolescent, and young adult cancer survivors. Guidelines for surveillance and management of potential adverse effects could improve cancer survivors' health and quality of life. Surveillance recommendations vary considerably, causing uncertainty about optimum screening practices. This clinical practice guideline recommended by the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium, developed using evidence-based methodology, critically synthesises surveillance recommendations for gonadotoxicity in male childhood, adolescent, and young adult (CAYA) cancer survivors. The recommendations were developed by an international multidisciplinary panel including 25 experts in relevant medical specialties, using a consistent and transparent process. Recommendations were graded according to the strength of underlying evidence and potential benefit gained by early detection and appropriate management. The aim of the recommendations is to enhance evidence-based care for male CAYA cancer survivors. The guidelines reveal the paucity of high-quality evidence, highlighting the need for further targeted research.
AB - Treatment with chemotherapy, radiotherapy, or surgery that involves reproductive organs can cause impaired spermatogenesis, testosterone deficiency, and physical sexual dysfunction in male pubertal, adolescent, and young adult cancer survivors. Guidelines for surveillance and management of potential adverse effects could improve cancer survivors' health and quality of life. Surveillance recommendations vary considerably, causing uncertainty about optimum screening practices. This clinical practice guideline recommended by the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium, developed using evidence-based methodology, critically synthesises surveillance recommendations for gonadotoxicity in male childhood, adolescent, and young adult (CAYA) cancer survivors. The recommendations were developed by an international multidisciplinary panel including 25 experts in relevant medical specialties, using a consistent and transparent process. Recommendations were graded according to the strength of underlying evidence and potential benefit gained by early detection and appropriate management. The aim of the recommendations is to enhance evidence-based care for male CAYA cancer survivors. The guidelines reveal the paucity of high-quality evidence, highlighting the need for further targeted research.
UR - http://www.scopus.com/inward/record.url?scp=85011933965&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(17)30026-8
DO - 10.1016/S1470-2045(17)30026-8
M3 - Review article
C2 - 28214419
AN - SCOPUS:85011933965
SN - 1470-2045
VL - 18
SP - e75-e90
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 2
ER -